ACROBiosystems/Mouse VEGF R2 / KDR Protein, Mouse IgG2a Fc Tag, low endotoxin/100ug/VE2

价格
¥36000.00
货号:VE2
浏览量:116
品牌:ACROBiosystems
服务
全国联保
正品保证
正规发票
签订合同
商品描述
  • Synonym
    KDR,CD309,FLK1,VEGFR,VEGFR2
  • Source
    Mouse VEGF R2, Mouse IgG2a Fc Tag, low endotoxin (VE2-M5258) is expressed from human 293 cells (HEK293). It contains AA Ala 20 - Glu 762 (Accession # P35918-1).
    Predicted N-terminus: Ala 20
    Request for sequence
  • Molecular Characterization
    Online(Ala 20 - Glu 762) P35918-1

    This protein carries a mouse IgG2a Fc tag at the C-terminus.

    The protein has a calculated MW of 110.1 kDa. The protein migrates as 120-135 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 0.1 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Mouse VEGF R2, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. VE2-M5258) SDS-PAGE gel

Mouse VEGF R2, Mouse IgG2a Fc Tag, low endotoxin on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA
Mouse VEGF R2, Mouse IgG2a Fc Tag, low endotoxinMouse VEGF R2, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. VE2-M5258) ELISA bioactivity

Immobilized ActiveMax® Human VEGF165, Tag Free (HPLC-verified) (Cat. No. VE5-H4210) at 2 μg/mL (100 μL/well) can bind Mouse VEGF R2, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. VE2-M5258) with a linear range of 1-31 ng/mL (QC tested).

Protocol
Mouse VEGF R2, Mouse IgG2a Fc Tag, low endotoxinMouse VEGF R2, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. VE2-M5258) ELISA bioactivity

Immobilized ActiveMax® Mouse VEGF120, Tag Free (Cat. No. VE0-M4211) at 2 μg/mL (100 μL/well) can bind Mouse VEGF R2, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. VE2-M5258) with a linear range of 1-31 ng/mL (Routinely tested).

Protocol
Mouse VEGF R2, Mouse IgG2a Fc Tag, low endotoxinMouse VEGF R2, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. VE2-M5258) ELISA bioactivity

Immobilized ActiveMax® Mouse VEGF164, Tag Free (HPLC-verified) (Cat. No. VE4-M4216) at 2 μg/mL (100 μL/well) can bind Mouse VEGF R2, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. VE2-M5258) with a linear range of 2-31 ng/mL (Routinely tested).

Protocol
  • Background
    Kinase insert domain receptor (KDR) is also known as CD309, FLK1, VEGFR, VEGFR2, andis one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF.The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi"s sarcoma lesions.
  • References
    • (1)Holmes K,et al., 2007, Cell Signal. 19 (10): 2003–2012.
    • (2)Stuttfeld E, et al., 2009,IUBMB Life 61 (9): 915–22.
    • (3)Fujita, N, et al., 2008, Biochem Biophys Res Commun, 372(2):367-72.
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

ACROBiosystems治疗性抗体的功效不仅取决于Fab片段及其与靶抗原的结合活性,还取决于Fc片段及其与关键Fc受体的相互作用。Fc片段对FcRn的结合亲和力(FCGRT&B2M)将预测抗体的半衰期,而Fc片段与FcγRIIIa(CD16a)之间的结合亲和力将影响抗体引发ADCC的能力(抗体依赖性细胞介导的细胞毒性)。因此,必须在抗体工程化过程中针对一组受体测试候选人。ACROBiosystems提供了完整的重组Fc受体蛋白集合,包括它们的常见变体,以帮助您加快mAb的开发。